Pranita D Tamma1, Edina Avdic2, John F Keenan3, Yuan Zhao4, Gobind Anand5, James Cooper6, Rebecca Dezube7, Steven Hsu8, Sara E Cosgrove9. 1. Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland, USA. 3. Department of Family Medicine, Lynchburg General and Virginia Baptist Hospital, Lynchburg, USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 5. Division of Gastroenterology, Department of Medicine, University of California, San Diego, USA. 6. Division of Hematology, Department of Medicine, National Institutes of Health, Bethesda, MD, USA. 7. Pulmonary and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. 8. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 9. Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
Background: The optimal approach to conducting antibiotic stewardship interventions has not been defined. We compared days of antibiotic therapy (DOT) using preprescription authorization (PPA) vs postprescription review with feedback (PPRF) strategies. Methods: A quasi-experimental, crossover trial comparing PPA and PPRF for adult inpatients prescribed any antibiotic was conducted. For the first 4 months, 2 medicine teams were assigned to the PPA arm and the other 2 teams to the PPRF arm. The teams were then assigned to the alternate arm for an additional 4 months. Appropriateness of antibiotic use was adjudicated by at least 2 infectious diseases-trained clinicians and according to institutional guidelines. Results: There were 2686 and 2693 patients admitted to the PPA and PPRF groups, with 29% and 27% of patients prescribed antibiotics, respectively. Initially, antibiotic DOTs remained relatively unchanged in the PPA arm. When changed to the PPRF arm, antibiotic use decreased (-2.45 DOT per 1000 patient-days [PD]). In the initial PPRF arm, antibiotic use decreased (slope of -5.73 DOT per 1000 PD) but remained constant when changed to the PPA arm. Median patient DOTs in the PPA and PPRF arms were 8 and 6 DOT per 1000 PD, respectively (P = .03). Antibiotic therapy was guideline-noncompliant in 34% and 41% of patients on days 1 and 3 in the PPA group (P < .01) and in 57% and 36% of patients on days 1 and 3 in the PPRF group (P = .03). Conclusions: PPRF may have more of an impact on decreasing antibiotic DOTs compared with PPA. This information may be useful for institutions without sufficient resources to incorporate both stewardship approaches.
RCT Entities:
Background: The optimal approach to conducting antibiotic stewardship interventions has not been defined. We compared days of antibiotic therapy (DOT) using preprescription authorization (PPA) vs postprescription review with feedback (PPRF) strategies. Methods: A quasi-experimental, crossover trial comparing PPA and PPRF for adult inpatients prescribed any antibiotic was conducted. For the first 4 months, 2 medicine teams were assigned to the PPA arm and the other 2 teams to the PPRF arm. The teams were then assigned to the alternate arm for an additional 4 months. Appropriateness of antibiotic use was adjudicated by at least 2 infectious diseases-trained clinicians and according to institutional guidelines. Results: There were 2686 and 2693 patients admitted to the PPA and PPRF groups, with 29% and 27% of patients prescribed antibiotics, respectively. Initially, antibiotic DOTs remained relatively unchanged in the PPA arm. When changed to the PPRF arm, antibiotic use decreased (-2.45 DOT per 1000 patient-days [PD]). In the initial PPRF arm, antibiotic use decreased (slope of -5.73 DOT per 1000 PD) but remained constant when changed to the PPA arm. Median patient DOTs in the PPA and PPRF arms were 8 and 6 DOT per 1000 PD, respectively (P = .03). Antibiotic therapy was guideline-noncompliant in 34% and 41% of patients on days 1 and 3 in the PPA group (P < .01) and in 57% and 36% of patients on days 1 and 3 in the PPRF group (P = .03). Conclusions: PPRF may have more of an impact on decreasing antibiotic DOTs compared with PPA. This information may be useful for institutions without sufficient resources to incorporate both stewardship approaches.
Authors: Anurag N Malani; Patrick G Richards; Shikha Kapila; Michael H Otto; Jennifer Czerwinski; Bonita Singal Journal: Am J Infect Control Date: 2012-05-10 Impact factor: 2.918
Authors: Anna C Sick; Christoph U Lehmann; Pranita D Tamma; Carlton K K Lee; Allison L Agwu Journal: Infect Control Hosp Epidemiol Date: 2013-04-18 Impact factor: 3.254
Authors: Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi Journal: Clin Infect Dis Date: 2016-05-15 Impact factor: 9.079
Authors: Peter Davey; Erwin Brown; Esmita Charani; Lynda Fenelon; Ian M Gould; Alison Holmes; Craig R Ramsay; Philip J Wiffen; Mark Wilcox Journal: Cochrane Database Syst Rev Date: 2013-04-30
Authors: Keith S Kaye; Tanaya Bhowmick; Symeon Metallidis; Susan C Bleasdale; Olexiy S Sagan; Viktor Stus; Jose Vazquez; Valerii Zaitsev; Mohamed Bidair; Erik Chorvat; Petru Octavian Dragoescu; Elena Fedosiuk; Juan P Horcajada; Claudia Murta; Yaroslav Sarychev; Ventsislav Stoev; Elizabeth Morgan; Karen Fusaro; David Griffith; Olga Lomovskaya; Elizabeth L Alexander; Jeffery Loutit; Michael N Dudley; Evangelos J Giamarellos-Bourboulis Journal: JAMA Date: 2018-02-27 Impact factor: 56.272
Authors: Melissa D Johnson; Russell E Lewis; Elizabeth S Dodds Ashley; Luis Ostrosky-Zeichner; Theoklis Zaoutis; George R Thompson; David R Andes; Thomas J Walsh; Peter G Pappas; Oliver A Cornely; John R Perfect; Dimitrios P Kontoyiannis Journal: J Infect Dis Date: 2020-08-05 Impact factor: 5.226